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Abstract
Background: The aim was to assess the incidence of prosthesis-patient mismatch (PPM) 
after mitral valve replacement (MVR) in patients receiving Biocor® porcine or mechanical 
valves, and to evaluate the effect of PPM on long-term survival.
Methods: All patients undergoing MVR between 2009 and 2013 received either mechanical or 
bioprosthetic valves (Biocor® porcine). PPM was defined as severe when the indexed effective ori-
fice area was < 0.9 cm2/m2, moderate between 0.9 cm2/m2 and 1.2 cm2/m2 or absent > 1.2 cm2/m2.  
The primary endpoint was all-cause long-term mortality.
Results: Among a total of 136 MVR, PPM was severe in 27%, moderate in 44% and absent 
in 29% of patients. Implanted valves were 57% mechanical and 43% bioprosthetic. Only 3% 
of patients with mechanical valves had severe PPM vs. 59% with bioprostheses (p < 0.0001). 
Sixty-month survival with severe mismatch was 0.559 (SE 0.149) and with no mismatch 
0.895 (SE 0.058) (p = 0.043). Survival of patients suffering from severe mismatch, or moderate 
mismatch with pulmonary hypertension (PH) was 0.749 (SE 0.101); while for patients with no 
mismatch or with moderate mismatch without PH, survival was 0.951 (SE 0.028) (p = 0.016).
Conclusions: About one-fourth of patients had severe PPM and almost all of them had re-
ceived a bioprosthesis. Sixty-month survival was significantly lower in patients with severe 
mismatch, or moderate mismatch with PH. Specifically, when a bioprothesis is chosen and 
while further evidence on the impact of PPM on clinical outcomes appears, surgeons are rec-
ommended to follow a preoperative strategy to implant a mitral prosthesis of adequate size in 
order to prevent PPM. (Cardiol J 2016; 23, 2: 178–183)
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Introduction
In contrast to prosthesis-patient mismatch 
(PPM) associated to aortic valve surgery, PPM 
after mitral valve replacement (MVR) is a concept 
rarely explored. Prosthesis-patient mismatch 
occurs when the effective orifice area (EOA) of 
the prosthetic valve is too small relatively to the 
patient’s body surface area (BSA), resulting in in-
creased postoperative transvalvular gradient. The 
ratio between EOA and BSA is known as indexed 
EOA (iEOA). Usually, moderate mitral PPM is 
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defined for iEOA £ 1.2 cm2/m2 and ≥ 0.9 cm2/m2; 
while severe mismatch is considered for iEOA 
< 0.9 cm2/m2.
At present, around two dozen retrospective 
cohort studies have been reported with controver-
sial outcomes about long-term survival of patients 
with severe mitral PPM [1]. Nevertheless, some 
evidence supports the notion that increased long-
term mortality in severe PPM may be associated to 
preoperative pulmonary hypertension (PH) [2, 3]. 
Recently, Aziz et al. [4] reported that severe PPM 
after MVR with bioprosthetic valves adversely af-
fects long-term survival in older patients. However, 
in this study, poor outcomes may be explained by 
confounding variables, since almost 25% of patients 
had undergone previous cardiac surgery, and 52% 
had received concomitant coronary or aortic sur-
gery procedures. Considering that bioprosthetic 
valves have in general lower EOA than mechani-
cal prostheses, and are preferentially implanted 
in older patients, further research is needed to 
evaluate the incidence of PPM in this age group. 
Furthermore, there is little information regarding 
the incidence of mitral PPM in older patients re-
ceiving the Biocor® porcine bioprosthesis (Biocor 
Industria e Pesquisas Ltda, Belo Horizonte, Brazil), 
in spite of being widely used in South American 
countries [5]. Based on these observations, the 
objective of this study was to assess the incidence 
of PPM after MVR in patients receiving Biocor® 
porcine prosthetic valves compared with mechani-
cal valves, and to evaluate the effect of mitral PPM 
on early mortality and long-term survival.
Methods
All patients undergoing MVR between 2009 
and 2013 at the Buenos Aires University Hospital 
of Argentina and its associated Clinics were in-
cluded in this study. Baseline and operative data 
were collected retrospectively from a clinical reg-
istry. Patients with concomitant procedures such 
as tricuspid annuloplasty, aortic valve replacement, 
or coronary artery bypass grafting were also in-
corporated. All the patients had standard surgical 
procedures for cardiopulmonary bypass through 
median sternotomy and transseptal biatrial ap-
proach. Cardiac arrest was obtained with antegrade 
infusion of St. Thomas solution and mild hypother-
mia. Implanted prostheses included mechanical 
and bioprosthetic valves. All tissue valves were 
Biocor® porcine bioprostheses, while mechani-
cal valves were of different types. Estimates of 
EOA for each valve type and size were obtained 
from reference normal values as summarized in 
Table 1. Indexed EOA was defined as prosthetic 
EOA divided by BSA, and PPM was defined as 
severe for iEOA < 0.9 cm2/m2, moderate for 
iEOA between 0.9 cm2/m2 and 1.2 cm2/m2 or ab-
sent for iEOA > 1.2 cm2/m2. Valve size selec-
tion relied on surgeon’s preference, and PPM 
was preset after the operation. Severe PH was 
defined as systolic pulmonary artery pressure 
> 55 mm Hg.
To assess long-term outcomes, postoperative 
follow-up was conducted by telephone interviews, 
questionnaires, or examination of hospital records. 
The endpoint was all-cause long-term mortality. 
The protocol was assessed and approved by the 
Institutional Ethics Committee (ENERI Ethics 
Committee; Chairperson Lylyk P.; file number of 
approval: ENERI-056; date of approval: November 
8th, 2014). No specific informed consent was re-
quired since this work was a retrospective analysis, 
and the institutional review board waived the need 
for patient consent.
Statistical analysis
Continuous variables were expressed as mean 
± standard deviation (SD) or standard error (SE). 
Kolmogorov-Smirnov goodness-of-fit test was used 
to analyze normal distributions. Univariate com-
parison of dichotomous variables was performed 
using c² and odds ratio (OR) with the associated 
95% confidence interval (95% CI). Yates’ corrected 
c² was used when cell expected values were be-
tween 3 and 5, and 2-tailed Fisher’s exact test when 
values were below 3. Continuous variables were 
compared using Student’s t test, Mann-Whitney U 
or ANOVA. The Kaplan-Meier method was used to 
assess the time-related survival probability. Sur-
vival curves were compared with the Mantel-Cox 
log-rank test. Statistical analysis was performed 
with SPSS Statistics for Windows, Version 17.0. 
Chicago, SPSS Inc. A 2-tailed p value £ 0.05 was 
considered statistically significant.
Results
Preoperative and intraoperative variables are 
shown in Table 1. For the total series of 136 MVR, 
PPM was severe in 27% (n = 36), moderate in 44% 
(n = 60) and absent in 29% (n = 40) of patients. 
Mechanical valves were implanted in 57% of cases 
(n = 78) and bioprostheses in 43% (n = 58). Table 2 
includes specific valve types; all the tissue valves im-
planted were Biocor® porcine prostheses [3, 6–10]. 
Table 3 summarizes selected preoperative and 
www.cardiologyjournal.org 179
Raul A. Borracci et al., Mismatch with mitral bioprostheses








Age [years] 67.0 ± 11.5 74.0 ± 5.64 67.3 ± 11.5 0.00008
Age ≥ 70 years 72 (52.9%) 51 (87.9%) 12 (15.4%) < 0.00001
Sex (female) 74 (54.4%) 33 (56.9%) 41 (52.6%) 0.616
Body surface area [m2] 1.84 ± 0.20 1.83 ± 0.20 1.84 ± 0.17 0.774
Pulmonary systolic pressure [mm Hg] 46.9 ± 11 49.3 ± 10.4 45.1 ± 11.6 0.031
Preoperative atrial fibrillation 49 (36.0%) 19 (32.8%) 30 (38.5%) 0.493
Emergent/urgent status 26 (19.1%) 9 (15.5%) 17 (21.8%) 0.357 
Endocarditis 14 (10.3%) 5 (8.6%) 9 (11.5%) 0.777
Ejection fraction < 50% 24 (17.6%) 12 (20.7%) 12 (15.4%) 0.422
Previous cardiac surgery 5 (3.7%) 2 (3.4%) 3 (3.8%) 1.000
EuroSCORE II (median, P25%,75%) [%] 2.34 (1.41–5.21) 2.49 (2.06–4.28) 1.51 (0.95–4.67) 0.043
Associated procedures:
Tricuspid annuloplasty 3 (2.2%) 0 (0.0%) 3 (2.2%) –
Aortic valve replacement 13 (9.6%) 6 (10.3%) 7 (9.0%) –
Coronary bypass surgery 15 (11.0%) 8 (13.8%) 7 (9.0%) –
Arrhythmia surgery 2 (1.5%) 0 (0.0%) 2 (1.5%) 0.213
Bypass time (median, P25%,75%) [min] 70.0 (60–88) 75.0 (60–90) 70.0 (60–89) 0.583
Cross-clamp time (median, P25%,75%) [min] 50.0 (40–60) 50.0 (45–60) 50.0 (40–60) 0.718
Chordal preservation 15 (11.0%) 6 (10.3%) 9 (11.5%) 1.000
Table 3. Patient characteristics based on the occurrence of prosthesis-patient mismatch (PPM) (n = 136).
Variable No PPM Moderate PPM Severe PPM P
Number of patients 40 (29%) 60 (44%) 36 (27%) –
Mean age [years] 65.1 ± 12.9 63.7 ± 11.8 74.1 ± 6.3 0.0001 
Age ≥ 70 years 20 (50%) 22 (37%) 30 (83%) < 0.0001
Female 26 (65%) 25 (42%) 23 (64%) 0.030
Body surface area [m2] 1.74 ± 0.17 1.89 ± 0.17 1.84 ± 0.19 0.0002 
Pulmonary pressure [mm Hg] 47.9 ± 12.1 44.8 ± 11.3 48.5 ± 12.6 0.614
Atrial fibrillation 11 (28%) 20 (35%) 18 (47%) 0.179
Emergent/urgent status 9 (23%) 8 (14%) 9 (24%) 0.392 
Bioprosthetic valve 10 (25%) 14 (23%) 34 (94%) < 0.0001
Emergent/urgent status includes endocarditis and postinfarction mitral valve dysfunction
Table 2. Types of prosthetic mitral valve implanted and effective orifice area based on reference  
normal values.
Effective orifice area [cm2] n 25 mm 27 mm 29 mm 31 mm 33 mm References
Mechanical valves:
ATS 8 1.8 ± 0.5 2.8 ± 0.3 2.8 ± 0.3 2.9 ± 0.2 2.9 ± 0.2 [6] 
Carbomedics 17 2.2 2.4 2.4 2.3 2.3 [3, 6]
On-X 4 2.2 ± 0.9 2.2 ± 0.9 2.2 ± 0.9 2.2 ± 0.9 2.2 ± 0.9 [3, 6]
St. Jude Medical 49 1.9 2.0 2.3 2.3 2.4 [3, 6, 7]
Bioprosthetic valves:
Biocor (SJM) 58 1.4 1.5 ± 0.3 2.3 ± 0.6 2.2 ± 0.6 2.3 ± 0.7 [8, 9, 10]
Effective orifice areas are expressed as mean or mean ± standard deviation
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intraoperative characteristics of patients based 
on the occurrence of PPM. Severe PPM was more 
common in older patients, women and in individu-
als receiving a bioprothethic valve. Only 3% (n = 2) 
of patients with mechanical valves had severe PPM 
vs. 59% (n = 34) of patients with bioprosthetic 
valves (p < 0.0001). Among the 34 Biocor® valves 
implanted and associated with severe mismatch, 
59% (n = 20) were 25 mm in diameter and the 
rest 27 mm. The incidence of moderate or severe 
PPM after mechanical and bioprosthetic MVR was 
not different in patients younger or older than 
70 years (Fig. 1).
Overall operative mortality was 9.6% (13/136 
patients) and isolated non-urgent MVR mortality 
was 6.3% (6/95 patients), while mortality after 
combined or urgent MVR was 15.5% (5/33 pa-
tients), showing worse results as the complexity 
of the procedure increased. Univariate analysis 
only identified previous mitral valve surgery to be 
associated with operative mortality (OR 7.27, 95% 
CI 1.09–48.3). Acute endocarditis (OR 3.05, 95% 
CI 0.73–12.8), urgent or emergent status (OR 1.30, 
95% CI 0.33–5.12), bioprosthetic valve implantation 
(OR 1.17, 95% CI 0.37–3.69) and severe PPM (OR 
0.81, 95% CI 0.21–3.15) failed to demonstrate an 
association with operative mortality. The total fol-
low-up period was 310.3 patient-years (mean time 
37 months). Sixty-month survival after MVR for pa-
tients with severe mismatch (iEOA < 0.9 cm2/m2) 
was 0.559 (SE 0.149). In contrast, long-term sur-
vival of patients with moderate mismatch (iEOA 
0.9–1.2 cm2/m2) was 0.937 (SE 0.043) and with no 
mismatch (iEOA > 1.2 cm2/m2) 0.895 (SE 0.058) 
(log rank p = 0.043) (Fig. 2). Cumulative survival 
of patients suffering from severe mismatch, or 
moderate mismatch with severe PH was 0.749 (SE 
0.101), while in patients with no mismatch or with 
moderate mismatch without severe PH, survival 
was 0.951 (SE 0.028) (log rank p = 0.016) (Fig. 3). 
Finally, for the group of patients exclusively receiv-
ing a bioprosthetic valve, long-term survival in the 
presence of severe PPM or moderate mismatch with 
PH was 0.440 (SE 0.169), while in individuals with 
no PPM, or with moderate mismatch without PH, 
survival was 0.766 (SE 0.125) (log rank p = 0.556).
Discussion
Approximately one-fourth of our patients 
undergoing MVR had severe PPM based on the 
immediate postoperative theoretical estimation, 
according to EOA reference values of each prosthe-
sis implanted. Furthermore, 94% of patients with 
severe PPM had received a bioprosthetic valve, and 
almost 60% of them had the smallest diameter bio-
prosthesis (Biocor® 25 mm). The overall incidence 
Figure 1. Incidence of prosthesis-patient mismatch 
(PPM) after mechanical and bioprosthetic mitral valve 
replacement in patients < 70 years and ≥ 70 years.
Figure 2. Kaplan-Meier cumulative 60-month survival, 
stratified by an indexed effective orifice area < 0.9 cm2/m2 
(severe mismatch group), between 0.9 and 1.2 cm2/m2 
(moderate mismatch group), or > 1.2 cm2/m2 (no mis-
match group).
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of PPM (iEOA ≤ 1.2 cm2/m2) after MVR ranges from 
3.7% to 85.9%; moderate PPM varies from 37.4% 
to 69.5%, and severe PPM from 8.7% to 16.4% 
[1, 3, 4, 7, 9, 11–14]. When considering values lower 
than 1.2 cm2/m2 to define PPM, Bouchard et al. [14] 
found only 3.7% of mismatch in patients receiving 
a mechanical valve. In contrast, Matsuura et al. [11] 
found 58.9% of PPM with the same cut-off value, 
including mechanical prostheses and approximately 
one-third of bioprosthesis.
Aziz et al. [4] observed that with mechanical 
valves the incidence of moderate or severe PPM 
was higher in patients younger than 65-years-old, 
while with bioprosthetic valves the incidence of 
PPM was higher in older patients. In the current 
study, an association between type of prosthesis, 
age and mismatch was not confirmed; neverthe-
less, the absence of statistical significance could 
depend on the power of the sample. Since bio-
prosthetic valves are commonly implanted in older 
people, we have concluded that PPM exclusively 
depends on the comparative lower EOA of biopros-
theses, with age acting as a confounding variable. 
Based on theoretical speculations, we established 
that by avoiding 25 mm-diameter Biocor® porcine 
valves, the incidence of severe PPM may be drasti-
cally reduced from 59% to 24%. Truly, one should 
abandon these small valves with small EOAs if 
there are other marketed valves of same outer ring 
Figure 3. Kaplan-Meier cumulative 60-month survival, 
stratified in two groups: severe mismatch or moder-
ate mismatch with systolic pulmonary artery pressure 
> 55 mm Hg vs. no mismatch or moderate mismatch 
with systolic pulmonary artery pressure ≤ 55 mm Hg.
diameter and larger EOAs. Nevertheless, this is 
not an intra-operative surgeon decision, but more 
a department strategy decision.
In addition to PPM, outcomes of MVR may 
be related to several other pathophysiological 
conditions, such as preoperative right and left 
ventricular function, mitral valve disease (steno-
sis or regurgitation), previous atrial fibrillation 
and PH, concomitant coronary artery bypass graft-
ing or aortic valve replacement, previous cardiac 
operation and preservation of mitral sub-valvular 
apparatus during surgery [1]. In our series, op-
erative mortality was significantly associated 
with previous mitral valve surgery, and poorer 
outcomes were also observed with combined 
surgery or urgent MVR.
Some evidence supports that only severe 
PPM is associated with higher mortality (HR: 
3.2, 95% CI 1.5–6.8), while moderate PPM does 
not significantly affect long-term survival [7]. 
On the contrary, other studies did not detect 
a deleterious impact of PPM on long-term sur-
vival after MVR [11–13, 15]; however, there 
is apparently an interaction between preop-
erative PH and long-term outcome in patients 
with both moderate and severe PPM [2, 3]. In 
our series, not only patients with severe mi-
tral PPM associated or not to preoperative PH 
but also those presenting moderate mismatch 
with preoperative systolic pulmonary pressure 
> 55 mm Hg showed lower long-term survival.
Most studies assessing long-term effects of 
mitral PPM practically only include patients with 
mechanical prosthesis, since they are less prone 
to late degenerative calcification that may change 
EOA over time, as occurs in those receiving a bio-
prosthesis. Therefore, the interpretation of these 
unpredictable bioprosthesis changes throughout 
time must be based on the theoretical estimation 
of immediate postoperative PPM. To eliminate 
a possible confounder, patients with mechanical 
prosthesis were removed for an extra survival 
analysis. In this case, comparative cumulative 
survival showed worse results in patients with 
severe PPM or moderate mismatch plus PH, in 
contrast to those having no mismatch or suffering 
a moderate PPM without PH. Nevertheless, the 
low power of the sample must be pondered again 
to interpret these findings.
Finally, though only a small proportion of our 
patients had posterior leaflet and chordal preserva-
tion to protect left ventricular function, this must 
be considered a common reason for implanting 
smaller prosthesis.
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The present study has some limitations. Firstly, 
its design was non-randomized and retrospective; 
hence, selection bias or unidentified confounders 
may have influenced the results. There are no 
uniform EOA values of Biocor® prosthesis in the 
literature and at present, no clear reference values 
have been firmly established for each valve size. 
Since iEOA is a hemodynamic measure and very 
much dependent on individualized hemodynamic 
conditions, EOA would have been ideally deter-
mined postoperatively for each patient’s prosthesis, 
but postoperative echocardiography showed to be 
inconsistent in the retrospective series [4]. There-
fore, estimates of EOA for each type and size were 
obtained from referenced normal values. Moreover, 
a probable high type II error must be considered 
when assessing factors associated with operative 
mortality. The major complication of porcine tissue 
valves in mitral position is structural valve dete-
rioration; hence, the resultant valve cusp calcifica-
tions may reduce EOA and worsen PPM. Another 
limitation of our work is that long-term structural 
deterioration or bioprosthesis dysfunction was not 
systematically assessed with echocardiography.
Conclusions
PPM after MVR is a poorly explored concept 
and current evidence is not conclusive to determine 
whether mitral PPM affects early mortality and 
long-term survival. In this study, approximately 
one-fourth of patients had severe PPM and almost 
all of them had received a bioprosthesis. PPM failed 
to demonstrate an association with operative mor-
tality; however, 60-month cumulative survival was 
significantly lower in patients suffering from severe 
mismatch, or moderate mismatch with severe PH. 
Especially, when a bioprothesis is chosen and while 
further evidence on the impact of PPM on clinical 
outcomes appears, surgeons are recommended to 
follow a preoperative strategy to implant a mitral 
prosthesis of adequate size in order to prevent PPM.
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